Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has outlined the scientific rationale supporting its lead drug candidate Xanamem® ...
The U.S. Food and Drug Administration (FDA) recently approved Leqembi, a drug indicated to treat Alzheimer’s disease in patients with mild cognitive impairment. The FDA granted Leqembi an Accelerated ...
Researchers created a 3D human brain tissue model using stem cells to model Alzheimer's plaque clearance and enable automated ...
A new study shows ImmunoBrain anti-PD-L1 antibody IBC-Ab002 is safe and reduces neurodegenerative biomarkers in Alzheimer's.
Seventy-nine percent of voters — including 78% of independents — support better access to coverage for Alzheimer’s detection ...
Dan Schwinnen doesn’t see himself as particularly gullible, but in a desperate attempt to obtain some medical relief in his mother-in-law’s battle against Alzheimer’s Disease, he took a ...
By detecting the subtle brain changes and damage to nerve cells years before memory or language issues surface, the blood test allows patients to seek treatment during the window when therapies are ...
People who lived within 50 km of a coal-fired power plant were 72.9% more likely to develop Alzheimer’s disease pathology ...
Readers respond to a Science Times article, “New Potential for Diagnosing Alzheimer’s Disease.” Also: The noise that data centers make.
Alzheimer's disease has traditionally been studied as a condition that primarily affects the brain's gray matter, where neuronal cell bodies are located and some of the disease's most characteristic ...
New studies point to the power of testing for and treating tau, a protein that builds up in Alzheimer’s disease, instead of just amyloid.
Eisai has launched LEQEMBI (lecanemab) in India after receiving CDSCO approval, introducing the country's first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results